Search

Your search keyword '"West, Michael L."' showing total 8 results
Start Over Author "West, Michael L." Publication Year Range This year
8 results on '"West, Michael L."'

3. FollowME Fabry Pathfinders Registry: Renal effectiveness in a cohort of patients on migalastat treatment for at least three years

Author

West, Michael L., primary, Hughes, Derralynn, additional, Sunder-Plassmann, Gere, additional, Jovanovic, Ana, additional, Brand, Eva, additional, Bichet, Daniel G., additional, Pisani, Antonio, additional, Nowak, Albina, additional, Torra, Roser, additional, Khan, Aneal, additional, Azevedo, Olga, additional, Lehman, Anna, additional, Linhart, Aleš, additional, Rutecki, Jasmine, additional, Giuliano, Joseph D., additional, Krusinska, Eva, additional, and Nordbeck, Peter, additional

Published
2024
Full Text
View/download PDF

4. Glycosphingolipid evaluation for Fabry disease patients receiving migalastat after switching from enzyme replacement therapy

Author

Auray-Blais, Christiane, primary, Lavoie, Pamela, additional, Martineau, Tristan, additional, Ntumba, Georges Kabala, additional, Gamrani, Mohamed, additional, Khan, Aneal, additional, Altarescu, Gheona, additional, Lehman, Anna, additional, Goker-Alpan, Ozlem, additional, Nowak, Albina, additional, West, Michael L., additional, and Bichet, Daniel G., additional

Published
2024
Full Text
View/download PDF

6. Facilitating intrafamily communication to enable earlier diagnosis of Fabry disease in relatives: Expert opinion

Author

Germain, Dominique P., primary, Al Murshedi, Fathiya, additional, Al Jasmi, Fatma, additional, Altarescu, Gheona, additional, Azevedo, Olga, additional, Barreto, Fellype C., additional, Ezgu, Fatih, additional, Laney, Dawn A., additional, Moiseev, Sergey, additional, Nochioka, Kotaro, additional, Ouyang, Yan, additional, Onay, Huseyin, additional, Pavlou, Mary, additional, Pachter, Nicholas, additional, Politei, Juan, additional, Sunbul, Rawda, additional, Steeds, Rick, additional, Yu, Wen-Chung, additional, West, Michael L., additional, Maski, Manish, additional, and Maksimova, Irina, additional

Published
2024
Full Text
View/download PDF

8. Renal and multisystem effectiveness of 3.9 years of migalastat in a global real-world cohort: Results from the followME Fabry Pathfinders registry.

Author

Hughes DA, Sunder-Plassmann G, Jovanovic A, Brand E, West ML, Bichet DG, Pisani A, Nowak A, Torra R, Khan A, Azevedo O, Lehman A, Linhart A, Rutecki J, Giuliano JD, Krusinska E, and Nordbeck P

Abstract

Fabry disease is a progressive, X-linked lysosomal disorder caused by reduced or absent α-galactosidase A activity due to GLA variants. The effects of migalastat were examined in a cohort of 125 Fabry patients with migalastat-amenable GLA variants in the followME Pathfinders registry (EUPAS20599), an ongoing, prospective, patient-focused registry evaluating outcomes for current Fabry disease treatments. We report annualised estimated glomerular filtration rate (eGFR) and Fabry-associated clinical events (FACEs) in a cohort of patients who had received ≥3 years of migalastat treatment in a real-world setting. As of August 2022, 125 patients (60% male) had a mean migalastat exposure of 3.9 years. At enrolment, median age was 58 years (males, 57; females, 60) with a mean eGFR of 83.7 mL/min/1.73 m 2 (n = 122; males, 83.7; females, 83.8) and a median left ventricular mass index of 115.1 g/m 2 (n = 61; males, 131.2; females, 98.0). Mean (95% confidence interval) eGFR annualised rate of change in the overall cohort (n = 116) was -0.9 (-10.8, 9.9) mL/min/1.73 m 2 /year with a similar rate of change observed across patients with varying levels of kidney function at enrolment. Despite population age and baseline morbidity, 80% of patients did not experience a FACE during the mean 3.9 years of migalastat exposure. The incidence of renal, cardiac, and cerebrovascular events was 2.0, 83.2, and 4.1 events per 1000 patient-years, respectively. These data support a role of migalastat in preserving renal function and multisystem effectiveness during ≥3 years of migalastat treatment in this real-world Fabry population., (© 2024 The Author(s). Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results